Indication
Hirobriz Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease.
Loading your page…
Loading your page…
Pulmonary Disease, Chronic Obstructive
Marketing Authorisation Holder: Novartis Europharm Limited
EMA Authorisation: 30/11/2009
INN: indacaterol
AI Drug & Interaction Analysis
Free account required
Ask Osler about Hirobriz Breezhaler: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.